BUTORPHANOL TARTRATE

Butorphanol tartrate is a synthetic opioid analgesic formulated to manage moderate to severe pain. It functions as a mixed agonist-antagonist at opioid receptors, a pharmacological profile designed to provide analgesia whilst reducing the potential for respiratory depression relative to full opioid agonists. The agent received initial approval for medical use in the United States in 1979. The intranasal formulation was subsequently approved in 1991, extending its clinical application to pain management without parenteral administration. Further regulatory approvals have been obtained in other countries over time, principally for hospital-based pain management, post-operative analgesia, trauma-related pain, and migraine pain episodes.

Butorphanol Tartrate is used for: Relief of moderate to severe acute pain Postoperative pain management Migraine attacks Pain during labour (under medical supervision) Other conditions requiring short-term opioid analgesia

Available as an intravenous injection for fast pain control in supervised medical environments. Supplied as an intramuscular injection when venous access is not used or not needed immediately. Offered in an intranasal spray for migraine pain and situations where injections are not suitable. Parenteral doses are given under a clinician's supervision with patient monitoring. The dosing interval is decided by pain severity, treatment setting and clinical response, often every 3 to 4 hours for short-term use based on physician assessment.

Common side effects include: Drowsiness or dizziness Nausea and vomiting Headache Sweating Dry mouth Less common or serious side effects: Respiratory depression Low blood pressure Heart rhythm disturbances Confusion or agitation Seek immediate medical attention if you experience severe breathing difficulty, chest pain, or signs of an allergic reaction.

May cause breathing slowdown, especially when combined with sedatives or other opioid medicines. It can cause sudden drops in blood pressure when administered rapidly into the bloodstream. Dependence and misuse potential exist; evaluate carefully in patients with a substance misuse history. May produce pronounced sleepiness, confusion or impaired alertness, affecting motor coordination or judgement. Severe allergic reactions can occur rarely; discontinue if swelling, rash or difficulty breathing develops. Use carefully in patients with head injury or raised intracranial pressure, as neurological symptoms may worsen.

Monitor heart rate, breathing rate and consciousness level during injection-based delivery. Use caution in older adults, who may experience stronger central effects or dizziness. Start at lower doses in liver or kidney impairment, as drug clearance may be slower. Avoid co-administration with alcohol or sleep-promoting medicines unless supervised medically. Assess fall risk due to dizziness or imbalance, particularly after dose administration. Use in pregnancy or breastfeeding only when a physician confirms the need after risk-benefit discussion. Limit therapy to short, medically guided courses when possible to reduce dependence likelihood.

https://pubchem.ncbi.nlm.nih.gov/compound/Butorphanol-Tartrate#section=Use-and-Manufacturing https://www.ncbi.nlm.nih.gov/books/NBK547902/ https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/19890s17lbl.pdf